The remaining 40% deploy machine- or deep-learning models to tackle harder problems, anticipating hypoglycemia, optimizing insulin dosing, estimating long-term complication risk, or extracting physiological signatures for personalized care [20,22,23,26,27]. This evidence concerns the gene INS and Hypoglycemia.